



WuXi Healthcare Forum 2019

Meeting Tomorrow's Health Challenges

March 5-6, 2019 | St. Regis, Shanghai

AGENDA

We are at the dawn of a new age in healthcare – global R&D is potentially on the brink of transformational productivity improvements, innovators are coming from ever more diverse backgrounds, and independent global markets are becoming increasingly connected.

Inspired by harnessing our collective wisdom to break down silos and acting boldly on new thinking, more than 2,000 global leaders will gather in Shanghai **March 5-6** to participate in the inaugural **WuXi Healthcare Forum 2019**. This event will celebrate what breakthroughs we have achieved, and will challenge us with the present realities and future possibilities. Spanning two unique days, the agenda will traverse the current universe from genomics to new diagnostics, from cancer treatments to the hard economics of paying for hospital care and, of course, new therapies. It's about widening the lens and seeing the technologies and scopes needed to improve health.



March 5, 9am - 5pm

MEDICINES FOR GLOBAL IMPACT

The opening day agenda focuses on novel medicines. We will explore how science, technology and entrepreneurship is driving a new age of geographically dispersed innovators, operating internationally to “bridge productivity” and expedite the development of better medicines.

- 7:30 - 9:00** **Registration**
- 9:00 - 9:05** **Welcome**
Hui Cai, Vice President, WuXi AppTec
- 9:05 - 9:20** **Opening Remarks**
Ge Li, Chairman, WuXi AppTec Group
- 9:20 - 10:00** **New Era. Golden Opportunities.**
Leaders from China and the UK explore how key stakeholders are redefining the innovation narrative – opening up a new era of opportunities and connecting the global ecosystem.
Ruilin Song, Executive President, China Pharmaceutical Innovation and Research Development Association
Steve Bates, CEO, UK BioIndustry Association
Leon Wang, Executive Vice President, International and China President of AstraZeneca
Edward Hu, Co-CEO, WuXi AppTec
Moderated by **Kevin Holland**, Minister-Counsellor and Director of Life Sciences, Healthcare and Social Care for China, British Embassy Beijing
- 10:00 - 10:40** **Medicines for Global Impact**
The development of tomorrow’s therapies has no boundaries. This session discusses how companies can work across borders and across technologies to bring about transformational changes wherever they can have the greatest impact.
Yongjun Liu, Global Head of Research, Sanofi
Lianshan Zhang, President, Global R&D, Jiangsu Hengrui Medicine Co.
Leon Chen, CEO & Founding Partner, 6 Dimensions Capital
George Chen, Sr. VP, Global R&D Oncology Unit; Head, R&D China, AstraZeneca
Damian O’Connell, CEO, Experimental Drug Development Centre, A*STAR
Moderated by **Steve Yang**, EVP, CBO, WuXi AppTec
- 10:40 - 11:00** **“Academic-Industry Collaboration in HIV Product Development and Scientific Inquiry”**
David Ho, Scientific Director and CEO, Aaron Diamond AIDS Research Center
History has shown it only takes one individual with a dream and dedication to make a difference. We hear from one such hero – David Ho.



- 11:00 - 11:20** **“Inflammation 2030 - Modern Diseases Caused by an Old Flame”**
Zhijian "James" Chen, George L. MacGregor Distinguished Chair in Biomedical Science, UT Southwestern Medical Center
James Chen - winner of the prestigious 2019 Breakthrough Prize in Life Sciences - will discuss his insights on ‘innate immunity’, which answered a century old mystery of DNA, and most importantly, how we might harness its potential.
- 11:20 - 12:00** **Where is the Next Disruption?**
It's time for some big ideas. We ask these leaders if they had a magic wand. What are their radical ideas to disrupt and improve R&D?
Bai Lu, Professor, School of Pharmaceutical Sciences, Tsinghua University
Jane Osbourn, Vice President R&D, MedImmune, Chair UK BiIndustry Association
John Oyler, Chairman, Co-Founder & CEO, BeiGene
Michael Yi, Partner, Hillhouse Capital Group
Moderated by **Nisa Leung**, Managing Partner, Qiming Venture Partners
- 12:00 - 13:30** **Lunch Break**
- 13:30 - 14:00** **Insights on US and China Regulatory Development**
An all-star panel of four former FDA/NMPA experts providing a spectrum of perspectives from small molecules to advanced therapies, and from quality to regulatory filing.
Ruyi He, Chief Scientific Officer, SDIC Fund Management
Michael Yi Yao, Co-Chairman, Gem Flower Pharma Tech
Gang Wang, Vice President for Quality and Global Regulatory Affairs, WuXi Biologics
Moderated by **Chiang Syin**, Chief Quality Officer, WuXi Biologics
- 14:00 - 14:40** **How to Deliver Global Success**
The industry's top practitioners discuss strategies to bring vital new medicines through the pipeline faster to patients at home and abroad.
Craig Anderson, Professor, University of New South Wales in Sydney; Executive Director, The George Institute for Global Health China
Zhengqing Li, CMO, President of R&D Greater China, Ascletic Pharma
Matt Cooper, Exec Director - Business Development & Marketing, National Institute for Health Research, UK
Carl Firth, CEO, ASLAN Pharmaceuticals
Jinzi J. Wu, Founder, Chairman and CEO, Ascletic Pharma
Moderated by **James Xue**, Chairman and CEO, CANbridge



14:40 - 15:00 **Coffee Break**

15:00 - 15:40 **The New Wave: Anti-Aging**

Here, we discuss, as new understandings of aging come to light, what age-related diseases are becoming significantly more prevalent, and how are scientists and entrepreneurs taking new approaches to tackle them?

Alex Zhavoronkov, Founder and CEO, Insilico Medicine

Eric Morgen, COO and CMO, BIOAGE

Karen Reeves, President and CMO, AZTherapies

Sang Hoon Lee, Founder and CEO, ABL Bio

Zhenyu Ju, Dean, Institute of Aging and Regenerative Medicine,
Jinan University

Moderated by **Guy Spigelman**, VP Portfolio Success, aMoon Fund

15:40 - 16:20 **The New Wave: Anti-Cancer**

A peek at some of the latest anti-cancer strategies and what impact can we expect them to have.

Ash Bahl, CSO and Head of R&D, Carrick Therapeutics

Zhengying Pan, Research Fellow, School of Chemical Biology & Biotechnology,
Peking University

Simone Botti, CEO, MetaboMed

Sofie Qiao, President and CEO, Vivace Therapeutics

Moderated by **Darren Ji**, Co-founder and CEO, Elpiscience; Venture Partner,
Lilly Asia Ventures

16:20 - 17:00 **The New Wave: Technologies**

New technologies are changing the face of R&D. How will our industry change in the next few years by taking full advantage of the opportunities technologies present?

Yanni Lin, Chief Technology Officer, CureGenetics

Jörg Weiser, Managing Director, Schrodinger

Misti Ushio, CEO, TARA Biosystem

Qi Liu, Professor, Bioinformatics Department in Tongji University

Ray Tabibiazar, Senior Vice President, Twist Bioscience

Moderated by **Naheed Kurji**, President and CEO, Cyclica



March 6, 9am - 5pm

THE NEW HEALTHCARE ECOSYSTEM

During day two, we take a broader look at health beyond therapy alone. Tomorrow's healthcare will go far further than prescribing drugs or performing surgery, it's about bringing in the wider lens and tools to improve patient care. A new "networked ecosystem" will be built upon vertically elevating the industry's strategy and horizontally harnessing our collective wisdom to break down silos, and act boldly on new thinking.

7:30 - 9:00

Registration

9:00 - 9:40

A Special Tribute to the Era of Transformation

During this special session, we use China and Asia as examples of how innovation hubs are started, catalyzed, and grown into full vibrancy. A reflection on a few historical "firsts."

Jonathan Wang, Partner, OrbiMed; Founding Partner, OrbiMed Asia

William Keller, Chairman, Coland Pharmaceuticals

Li Chen, CEO, Hua Medicine

Chris Chen, CEO, WuXi Biologics

Moderated by **Greg Scott**, Founder and CEO, ChinaBio

9:40 - 10:20

The New Age of Global Innovation

The future will be defined by accelerated global connections and a networked ecosystem – whether from Boston to Osaka, or San Diego to Shanghai. But what new strategies are required for innovators to take advantage of global opportunities for product development, partnership and investment?

Dan Wang, Head of Johnson & Johnson Innovation, Asia Pacific

Curtis Keith, CSO, Blavatnik Biomedical Accelerator, Harvard University

Robert S. Sullivan, Dean, Rady School of Management, UC San Diego

Toshio Fujimoto, General Manager, Takeda Shonan Innovation Park, Takeda

Sophie Sun, Managing Director, Merck Innovation Hub China

Moderated by **David Flores**, Co-Founder, President and CEO, BioCentury

10:20 - 10:40

The New Healthcare Ecosystem – Perspectives from the Financial Markets

A Conversation with **Ken Hitchner**, Chairman and CEO, Asia Pacific Ex-Japan, Goldman Sachs

Now we zoom into the future of Asia Pacific - one of the most dynamic and diverse regions in the world with 60% of the world's population, huge unmet health needs, and a large proportion of future global economic growth.

Moderated by **Yibing Wu**, Joint Head, Enterprise Development Group & Head, China, Temasek



- 10:40 - 11:20 The Healthcare Disruption**
How will we go about creating the robust platforms that ultimately will provide disruptive healthcare solutions? What the healthcare landscape might look like as it faces ever changing political and economic climate, and new technologies?
Andy Lin, Founding Partner, Loyal Valley Capital
Lee Ligang Zhang, Founder, Chairman and CEO, iKang Healthcare Group
Jiangnan Cai, Director, CEIBS Centre for Health Care Management and Policy
Moderated by **Feng Deng**, Founding Managing Director, Northern Light Venture Capital
- 11:20 - 12:00 Balancing Medical Innovation and Access**
Across the world, accessibility and affordability are always at the center of the healthcare debate. How do we make sure patients get the healthcare they need? Can we balance costs and the need for innovation? Can big data and artificial intelligence help? This session provides a holistic appraisal from prominent players.
Rong Yu, Chairman, Meinian Onehealth Healthcare Group; Chairman, Tianyi Investment Group
Bin Li, Partner and Managing Director, Ally Bridge Group
Guang Ning, Vice President, Ruijin Hospital of Shanghai Jiaotong University
Chunpeng Hao, Deputy Secretary-General, China Health Insurance Research Association
Qingfeng Zhai, Senior Executive, China Life Reinsurance Company
Moderated by **Wilson Zhang**, Chief Strategy Officer, WuXi AppTec
- 12:00 - 13:30 Lunch Break**
- 13:30 - 14:10 Delivering Clinical Precision through Genomics**
Genomics is finally ready for prime time. What does it mean to know what's in your genes? What does genomic medicine mean for China? How do we bring about clinical precision and personalized medicine using genomic insights?
Wenhao Zhou, VP, Children's Hospital of Fudan University
Gang Chen, CEO, WeGene
Kai Wang, Founder and CEO, OrigiMed
Moderated by **Sijia Lu**, CEO, Yikon Genomics
- 14:10 - 14:50 Diagnosing the Future**
Advanced Clinical Diagnostic testing has grown rapidly in recent years, and has become a key part of precision medicine. What are the latest trends in global diagnostic testing development? How can China's Clinical Diagnostic sector learn



from its global peers, and develop a unique path suitable for its patients? Where are the new markets and investment opportunities? How do we effectively build an ecosystem for future Diagnostics?

William Morice, President, Mayo Clinic Laboratories

Daozhi Liu, Founding Partner, Sunland Capital

Martien van Osch, Managing Partner, Forbion

Yaoyi Zhu, Chairman, IVD Branch, China Association for Medical Devices Industry

Moderated by **Jason Liu**, CEO, WuXi Diagnostics

14:50 - 15:10 **Coffee Break**

15:10 - 15:30 **“Do’s and Don’ts of Internet Healthcare Industry Development”**

Stanley Li, Chairman and President, DXY

15:30 - 16:15 **The Data Inspiration**

We postulate... How to improve data collection? Who owns data? How to break down the data silos? How will a data-driven future look like?

Tony Zhang, Founder and CEO, LinkDoc Technology

Andy Liu, CEO, CW Data Technologies

Choo Chiap Chiau, AI Lab Director, Philips Research Asia

Moderated by **Hong Li**, Vice President, Digital China Health Technologies

16:15 - 17:00 **The Patient Care Revolution**

The revolution in healthcare is being led by patients, who are now more empowered than ever. They are demanding more choice and transparency and harnessing technology to garner the best information to weigh their options and be in greater control of their care. What would tomorrow’s patient care look like? How will the newly empowered consumers drive disruption and change? And how we can navigate the path forward – using AI, machine learning and other technologies to transform public health?

Meng Zhang, General Manager, Tencent Health

Ning Hou, COO, XiKang

Xiaodong Tao, Vice President of iFlytek; CEO of iFlytek Healthcare

Fay Xing, CEO, PICA Health

Moderated by **Xinxin Gao**, CEO and Founding Partner, Jiangmen

17:00 **Closing Remarks & Adjourn**

Edward Hu, Co-CEO, WuXi AppTec